BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 18590557)

  • 1. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells.
    Fandy TE; Shankar S; Srivastava RK
    Mol Cancer; 2008 Jun; 7():60. PubMed ID: 18590557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
    Ng CP; Bonavida B
    Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro.
    Mao HL; Liu PS; Zheng JF; Zhang PH; Zhou LG; Xin G; Liu C
    Pharmacol Res; 2007 Dec; 56(6):483-92. PubMed ID: 18029193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
    Bockbrader KM; Tan M; Sun Y
    Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis.
    Guo F; Nimmanapalli R; Paranawithana S; Wittman S; Griffin D; Bali P; O'Bryan E; Fumero C; Wang HG; Bhalla K
    Blood; 2002 May; 99(9):3419-26. PubMed ID: 11964312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.
    Servida F; Lecis D; Scavullo C; Drago C; Seneci P; Carlo-Stella C; Manzoni L; Polli E; Lambertenghi Deliliers G; Delia D; Onida F
    Invest New Drugs; 2011 Dec; 29(6):1264-75. PubMed ID: 20614162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bypassing the need for pre-sensitization of cancer cells for anticancer TRAIL therapy with secretion of novel cell penetrable form of Smac from hA-MSCs as cellular delivery vehicle.
    Khorashadizadeh M; Soleimani M; Khanahmad H; Fallah A; Naderi M; Khorramizadeh M
    Tumour Biol; 2015 Jun; 36(6):4213-21. PubMed ID: 25586349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria.
    Zhang XD; Zhang XY; Gray CP; Nguyen T; Hersey P
    Cancer Res; 2001 Oct; 61(19):7339-48. PubMed ID: 11585775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
    Nagy K; Székely-Szüts K; Izeradjene K; Douglas L; Tillman M; Barti-Juhász H; Dominici M; Spano C; Luca Cervo G; Conte P; Houghton JA; Mihalik R; Kopper L; Peták I
    Pathol Oncol Res; 2006; 12(3):133-42. PubMed ID: 16998592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
    Kandasamy K; Srinivasula SM; Alnemri ES; Thompson CB; Korsmeyer SJ; Bryant JL; Srivastava RK
    Cancer Res; 2003 Apr; 63(7):1712-21. PubMed ID: 12670926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release.
    Mohr A; Büneker C; Gough RP; Zwacka RM
    Oncogene; 2008 Jan; 27(6):763-74. PubMed ID: 17653087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L.
    Pieczykolan JS; Kubiński K; Masłyk M; Pawlak SD; Pieczykolan A; Rózga PK; Szymanik M; Gałązka M; Teska-Kamińska M; Żerek B; Bukato K; Poleszak K; Jaworski A; Strożek W; Świder R; Zieliński R
    Invest New Drugs; 2014 Dec; 32(6):1155-66. PubMed ID: 25182378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells.
    Roa WH; Chen H; Fulton D; Gulavita S; Shaw A; Th'ng J; Farr-Jones M; Moore R; Petruk K
    Clin Invest Med; 2003 Oct; 26(5):231-42. PubMed ID: 14596484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria.
    Zhang XD; Borrow JM; Zhang XY; Nguyen T; Hersey P
    Oncogene; 2003 May; 22(19):2869-81. PubMed ID: 12771938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired kinetics of Bax-GFP and Smac/DIABLO-GFP in caspase-8- and bid-silenced and Bcl-2 overexpressed breast cancer MCF-7 cells exposed to camptothecin.
    Górka M; Lamparska-Przybysz M; Motyl T
    Cell Mol Biol (Noisy-le-grand); 2007 Jan; 52 Suppl():OL915-22. PubMed ID: 17666167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.
    Fulda S; Wick W; Weller M; Debatin KM
    Nat Med; 2002 Aug; 8(8):808-15. PubMed ID: 12118245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-overexpression of TRAIL and Smac sensitizes MDA-MB-231 cells to radiation through apoptosis depending on mitochondrial pathway.
    Xu W; Fang F; Wang Y; Qin L; Han Y; Huang Y; Li B; Liu Y; Wang Z
    Radiat Environ Biophys; 2022 Mar; 61(1):37-48. PubMed ID: 35006369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.
    Petrucci E; Pasquini L; Petronelli A; Saulle E; Mariani G; Riccioni R; Biffoni M; Ferretti G; Benedetti-Panici P; Cognetti F; Scambia G; Humphreys R; Peschle C; Testa U
    Gynecol Oncol; 2007 May; 105(2):481-92. PubMed ID: 17292950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis.
    Zhou S; Huang Q; Zheng S; Lin K; You J; Zhang X
    Tumour Biol; 2016 May; 37(5):6837-45. PubMed ID: 26662313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis.
    Yang C; Ran Q; Zhou Y; Liu S; Zhao C; Yu X; Zhu F; Ji Y; Du Q; Yang T; Zhang W; He S
    Apoptosis; 2020 Jun; 25(5-6):441-455. PubMed ID: 32418059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.